Elegen , a leading next-generation DNA manufacturer, and Nutcracker Therapeutics , a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics…
CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment Today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory…
A global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer…
Parse Biosciences, a leading provider of easy-to-use and scalable single-cell sequencing solutions, today announced that a groundbreaking study published in Science used Parse’s single-cell technology to reveal how signaling pathways drive the formation of multiple neuronal subtypes. By linking specific signals to cell fate…
Artificial Intelligence in Clinics Set to Transform Diagnostic Practices – ResearchAndMarkets.com Smart In-Vitro Diagnostics Market Report Highlights the Growing Role of AI in Healthcare New report from ResearchAndMarkets.com explores how artificial intelligence is transforming the in-vitro diagnostics (IVD) industry. A…
iFIT Teams Up with Samsung Health to Offer Personalized Fitness and Wellness Experiences Globally iFIT, a global leader in connected fitness devices and interactive content, today announced a groundbreaking partnership with Samsung Health, one of the most trusted names in…
Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer Today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization…
BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in…
KVC Health Systems and WellSky® Partner to Improve Behavioral Health Care WellSky, a global health and community care technology and services company, today announced that KVC Health Systems, a national leader in mental health, child welfare, and health and human services…
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services…